$JNJ announces its Q2 2025 earnings: EPS at $2.77, beating estimates by $0.09, with revenue at $23.74B (+5.77% YoY). Notably, 13 brands reported double-digit growth despite challenges from STELARA's biosimilar competition. 🚀 Key highlights in growth (4.6%) across diverse sectors, especially Innovative Medicine and MedTech. Future prospects look solid, with important product launches ahead. 📈 However, watch for risks related to market competition and increased debt from acquisitions. For more details, check valueverge.com/JNJ.